Clinical Trials
13 trialsNCT00571662 2023-10-24
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Phase 2 Completed
NCT02593123 2023-01-23
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Phase 2 Completed
NCT00488592 2021-07-12
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00003727 2019-11-04
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Phase 2 Completed
NCT00363649 2018-11-13
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00466726 2018-08-28
CML0206
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT00072579 2017-01-19
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
Wake Forest University Health Sciences
Phase 2 Completed
NCT00446173 2015-08-25
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00011934 2014-04-17
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00002778 2011-07-20
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00003561 2011-07-20
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated